Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [18F]FDG‐PET
暂无分享,去创建一个
M Samii | G. Nikkhah | D. Brooks | J. van den Hoff | M. Samii | R. Dengler | T. Peschel | G. Berding | W. Knapp | P. Odin | C. Matthies | C Matthies | G Nikkhah | D J Brooks | G Berding | P Odin | T Peschel | M Shing | H Kolbe | J van Den Hoff | H Fricke | R Dengler | W H Knapp | H. Fricke | H. Kolbe | M. Shing
[1] D E Kuhl,et al. Patterns of local cerebral glucose utilization determined in Parkinson's disease by the [18F]fluorodeoxyglucose method , 1984, Annals of neurology.
[2] J R Moeller,et al. Early differential diagnosis of Parkinson's disease with 18F‐fluorodeoxyglucose and positron emission tomography , 1995, Neurology.
[3] G Blomqvist,et al. On the Construction of Functional Maps in Positron Emission Tomography , 1984, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[4] S. Fahn. Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .
[5] D. Kuhl,et al. Neurochemical imaging of Alzheimer's disease and other degenerative dementias. , 1998, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.
[6] T. Goldberg,et al. Neuropsychological and Glucose Metabolic Profiles in Asymmetric Parkinson’s Disease , 1992, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[7] M. M. Burns,et al. Parkinsonism , 1975, Neurology.
[8] J O Rinne,et al. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study. , 2000, Archives of neurology.
[9] K. Leenders,et al. Long‐term changes of striatal dopamine D2 Receptors in patients with Parkinson's disease: A study with positron emission tomography and [11C]Raclopride , 1997, Movement disorders : official journal of the Movement Disorder Society.
[10] M. Hoehn,et al. Parkinsonism , 1967, Neurology.
[11] D E Kuhl,et al. Determination of regional rate constants from dynamic FDG-PET studies in Parkinson's disease. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[12] M. Torrens. Co-Planar Stereotaxic Atlas of the Human Brain—3-Dimensional Proportional System: An Approach to Cerebral Imaging, J. Talairach, P. Tournoux. Georg Thieme Verlag, New York (1988), 122 pp., 130 figs. DM 268 , 1990 .
[13] C. Marsden,et al. 'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. , 1988, Brain : a journal of neurology.
[14] P. Pollak,et al. Relief of akinesia by apomorphine and cerebral metabolic changes in parkinson's disease , 1993, Movement disorders : official journal of the Movement Disorder Society.
[15] W. Poewe,et al. High‐speed memory scanning in Parkmson's disease: Adverse effects of levodopa , 1991, Annals of neurology.
[16] Richard S. J. Frackowiak,et al. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C‐raclopride and positron emission tomography , 1992, Annals of neurology.
[17] D. Brooks,et al. PET and the investigation of dementia in the parkinsonian patient. , 1997, Journal of neural transmission. Supplementum.
[18] A. Bonnet,et al. [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.
[19] E. Růžička,et al. Apomorphine induced cognitive changes in Parkinson's disease. , 1994, Journal of neurology, neurosurgery, and psychiatry.
[20] R. C. Collins,et al. Metabolic effects of unilateral lesion of the substantia nigra , 1981, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[21] A. Lang,et al. Parkinson's disease. First of two parts. , 1998, The New England journal of medicine.
[22] J. Growdon,et al. Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients , 1998, Neurology.
[23] E. Hoffman,et al. TOMOGRAPHIC MEASUREMENT OF LOCAL CEREBRAL GLUCOSE METABOLIC RATE IN HUMANS WITH (F‐18)2‐FLUORO-2‐DEOXY-D‐GLUCOSE: VALIDATION OF METHOD , 1980, Annals of neurology.
[24] William J. Jagust,et al. Cortical glucose metabolism in Parkinson's disease without dementia , 1994, Neurobiology of Aging.
[25] Niels Birbaumer,et al. Memory and Skill Acquisition in Parkinson's Disease and Frontal Lobe Dysfunction , 1995, Cortex.
[26] C S Patlak,et al. Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[27] D. Stein,et al. Bilateral frontal cortical contusion in rats: behavioral and anatomic consequences. , 1994, Journal of neurotrauma.
[28] B. Sahakian,et al. Thalamic radiodensity and cognitive performance in mild and moderate dementia of the Alzheimer type. , 1993, Journal of psychiatry & neuroscience : JPN.
[29] K Herholz,et al. FDG PET and Differential Diagnosis of Dementia , 1995, Alzheimer disease and associated disorders.
[30] T. Robbins,et al. Dissociation in prefrontal cortex of affective and attentional shifts , 1996, Nature.
[31] C. Patlak,et al. Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data. Generalizations , 1985, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[32] V J Cunningham,et al. Cortical dysfunction in non-demented Parkinson's disease patients: a combined (31)P-MRS and (18)FDG-PET study. , 2000, Brain : a journal of neurology.
[33] K. Hamacher,et al. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[34] Kengo Ito,et al. Parieto-occipital glucose hypometabolism in Parkinson’s disease with autonomic failure , 1999, Journal of the Neurological Sciences.
[35] V Kaasinen,et al. Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson’s disease , 2000, Neurology.
[36] C. Marsden,et al. Fronto-striatal cognitive deficits at different stages of Parkinson's disease. , 1992, Brain : a journal of neurology.
[37] T. Ishikawa,et al. The Metabolic Topography of Parkinsonism , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[38] A. Lang,et al. Parkinson's disease. Second of two parts. , 1998, The New England journal of medicine.
[39] T. Robbins,et al. Probabilistic learning and reversal deficits in patients with Parkinson’s disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication , 2000, Neuropsychologia.
[40] M P Witter,et al. Neuropsychological correlates of a right unilateral lacunar thalamic infarction , 1999, Journal of neurology, neurosurgery, and psychiatry.
[41] T. Robbins,et al. Specific cognitive deficits in mild frontal variant frontotemporal dementia. , 1999, Brain : a journal of neurology.
[42] A. Lees,et al. A clinicopathologic study of 100 cases of Parkinson's disease. , 1993, Archives of neurology.
[43] V. Dhawan,et al. Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET , 1998, Movement disorders : official journal of the Movement Disorder Society.
[44] Karl J. Friston,et al. Rapid Assessment of Regional Cerebral Metabolic Abnormalities in Single Subjects with Quantitative and Nonquantitative [18F]FDG PET: A Clinical Validation of Statistical Parametric Mapping , 1999, NeuroImage.
[45] H J Sagar,et al. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients. , 1992, Brain : a journal of neurology.
[46] R J Wise,et al. The effects of L-DOPA on regional cerebral blood flow and oxygen metabolism in patients with Parkinson's disease. , 1985, Brain : a journal of neurology.
[47] D E Kuhl,et al. Motor correlates of occipital glucose hypometabolism in Parkinson’s disease without dementia , 1999, Neurology.
[48] J. Saint-Cyr,et al. Frontal lobe dysfunction in Parkinson's disease. The cortical focus of neostriatal outflow. , 1986, Brain : a journal of neurology.
[49] P. Mcgeer,et al. Cortical glucose metabolism in parkinson's and alzheimer's disease , 1990, Journal of neuroscience research.
[50] M. Sasaki,et al. Differentiating between multiple system atrophy and Parkinson’s disease by positron emission tomography with18F-dopa and18F-FDG , 1997, Annals of nuclear medicine.
[51] J. Kulisevsky,et al. Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson's disease patients at different levodopa plasma levels. , 1996, Brain : a journal of neurology.
[52] E. Hoffman,et al. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F‐18)2‐fluoro‐2‐deoxy‐D‐glucose: Validation of method , 1979, Annals of neurology.